ALSO NOTED: ImaRx prices IPO; Sepracor, Eisai sign deal for Lunesta; and much more...
Free newsletter via e-mail
Tools
> GSK has decided not to exercise its option to license Exelixis' non-small cell lung cancer drug XL647 for further development. Release
> ImaRX Therapeutics has priced its IPO at $5 per share. Release
> Chutes & Ladders: Silence Therapeutics has appointed Jeffery Scott Vick as Group CEO. Release
> Sepracor and Eisai have signed a deal development and commercialization of Sepracor's sleep drug Lunesta for the Japanese market. Release
And Finally... According to a Wake Forest University School of Medicine study, a class of drugs (which included Avandia and Actos) used to treat type 2 diabetes may double the risk of heart failure. Report
SHARE
WITH: